滋阴清热通窍方防治放射治疗损伤的临床研究

注册号:

Registration number:

ITMCTR2025000724

最近更新日期:

Date of Last Refreshed on:

2025-04-13

注册时间:

Date of Registration:

2025-04-13

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

滋阴清热通窍方防治放射治疗损伤的临床研究

Public title:

Clinical Study of Ziyinqingretongqiao Prescription for Prevention and Treatment of Radiation Therapy Injury

注册题目简写:

English Acronym:

研究课题的正式科学名称:

滋阴清热通窍方防治放射治疗损伤的临床研究

Scientific title:

Clinical Study of Ziyinqingretongqiao Prescription for Prevention and Treatment of Radiation Therapy Injury

研究课题的正式科学名称简写:

中药方防治放射损伤

Scientific title acronym:

Herbal Prescription for Radiation therapy Injury

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈奕涵

研究负责人:

刘剑锋

Applicant:

Chen Yihan

Study leader:

Liu Jianfeng

申请注册联系人电话:

Applicant telephone:

15910590552

研究负责人电话:

Study leader's telephone:

13621373926

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yihanchen28@163.com

研究负责人电子邮件:

Study leader's E-mail:

mmconfucius@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区北三环东路11号

研究负责人通讯地址:

北京市朝阳区樱花园东街2号

Applicant address:

No. 11 East North Third Ring Road Chaoyang District. Beijing

Study leader's address:

2 CherryBlossom Street East Chaoyang District. Beijing

申请注册联系人邮政编码:

Applicant postcode:

100029

研究负责人邮政编码:

Study leader's postcode:

100029

申请人所在单位:

中日友好医院,北京中医药大学,北京

Applicant's institution:

China-Japan Friendship Hospital Beijing University of Chinese Medicine Beijing

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2025-KY-073

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

中日友好医院临床伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of China-Japan Friendship Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025/3/24 0:00:00

伦理委员会联系人:

崔勇

Contact Name of the ethic committee:

Cui Yong

伦理委员会联系地址:

北京市朝阳区樱花东街2号

Contact Address of the ethic committee:

2 CherryBlossom Street East Chaoyang District.Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8420 6250

伦理委员会联系人邮箱:

Contact email of the ethic committee:

wuhucuiyong@vip.163.com

研究实施负责(组长)单位:

中日友好医院

Primary sponsor:

China-Japan Friendship Hospital

研究实施负责(组长)单位地址:

北京市朝阳区樱花东街2号

Primary sponsor's address:

2 CherryBlossom Street East Chaoyang District.Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

朝阳区

Country:

China

Province:

Beijing

City:

Chaoyang

单位(医院):

中日友好医院

具体地址:

北京市朝阳区樱花东街2号

Institution
hospital:

China-Japan Friendship Hospital

Address:

2 CherryBlossom Street East Chaoyang District.Beijing

经费或物资来源:

自发性研究

Source(s) of funding:

Investigator Initiated Trial

研究疾病:

头颈部恶性肿瘤

研究疾病代码:

Target disease:

Head and neck malignancies

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

队列研究

Cohort study

研究所处阶段:

Study phase:

其它

Others

研究目的:

①确定滋阴清热通窍方在头颈部恶性肿瘤患者放射损伤的防治作用:本研究旨在通过前瞻性队列研究,验证滋阴清热通窍方作为一种中医药治疗方式,在防治放射性鼻-鼻窦炎、嗅觉味觉功能障碍方面的疗效。②探索中药鼻腔冲洗、雾化吸入对放射治疗患者鼻黏膜纤毛传输功能的影响。③评估滋阴清热通窍方对放射治疗患者嗅觉味觉功能的影响。

Objectives of Study:

① To determine the prevention and treatment effect of Ziyinqingretongqiao Prescription on radiation injury in patients with head and neck malignant tumors: The purpose of this study was to verify the efficacy of Ziyinqingretongqiao prescription as a traditional Chinese medicine treatment in the prevention and treatment of radiation rhinosinusitis and olfaction and taste dysfunction through a prospective cohort study. ② To explore the effect of nasal irrigation and nebulization of traditional Chinese medicine on the transmission function of nasal mucociliary tract in patients with radiotherapy. ③ To evaluate the effect of Ziyinqingretongqiao prescription on the olfactory and taste function of radiotherapy patients.

药物成份或治疗方案详述:

①在对症处理基础上预防性应用过中药滋阴清热通窍方浓煎100ml,其中80 ml进行鼻腔冲洗、10ml进行20min雾化吸入。②每日一剂,患者自行在生理盐水鼻冲洗后,双侧鼻腔冲洗后雾化吸入,早晚各一次。在第一次放射治疗前即开始应用,在放射治疗结束前完成一个疗程(14天)。药物组成如下:苍耳子10g,辛夷15g,白芷15g,薄荷10g,北沙参9g,黄芩12 g,川芎6 g,皂角刺6 g,野菊花10 g,鱼腥草10 g,石斛6g,麦冬12 g,五味子6 g,黄芪15 g,甘草10 g。

Description for medicine or protocol of treatment in detail:

① On the basis of symptomatic treatment 100ml of the traditional Chinese medicine Ziyinqingretongqiao decoction was prophylactically applied of which 80 ml was rinsed nasal cavity and 10ml was atomized inhalation for 20min. (2) One dose per day after nasal irrigation with normal saline and atomized inhalation after bilateral nasal irrigation once in the morning and once in the evening. It is started before the first radiotherapy and one course of treatment (14 days) is completed before the end of radiotherapy. The drug composition was as follows: Xanthium 10g Xinyi 15g Angelica 15g Menthol 10g Radix saponae 9g Scutellaria 12g Chuanxiong 6g Radix saponae 6g wild chrysanthemum 10g Houttuynia 10g Dendrobium ophiopogon 12g Schisandra chinensis 6g Radix Astragalus 15g licorice 10g.

纳入标准:

①经病理活检确诊的鼻腔、鼻窦、颅底及鼻咽部恶性肿瘤放射治疗患者,年龄18-70岁,性别不限;②未发生复发转移及颅内异常疾病;③一般认知功能正常,日常生活能力基本正常,无听觉、视觉、语言等功能障碍;④符合以上诊断标准并对本研究知情同意。

Inclusion criteria

① Patients with malignant tumors of nasal cavity sinus skull base and nasopharynx confirmed by pathological biopsy aged 18-70 years old regardless of gender; ② There was no recurrence metastasis and abnormal intracranial diseases; ③ General cognitive function is normal the ability of daily living is basically normal no auditory visual language and other functional disorders; ④ Meet the above diagnostic criteria and give informed consent to this study.

排除标准:

①放射治疗前即明确诊断为过敏性鼻炎、鼻窦炎,经长期治疗无明显好转者;②肝肾功明显异常,或对滋阴清热通窍方成分过敏者;③预计生存时间不足3个月者;④无法配合者。

Exclusion criteria:

① Patients who were diagnosed with allergic rhinitis and sinusitis before radiotherapy and did not improve significantly after long-term treatment; (2) Obvious abnormal liver and kidney function or allergic to the ingredients of Ziyin Qingheat Tongqiao recipe; ③ the expected survival time is less than 3 months; ④ unable to cooperate.

研究实施时间:

Study execute time:

From 2025-04-14

To      2026-12-31

征募观察对象时间:

Recruiting time:

From 2025-04-15

To      2026-10-31

干预措施:

Interventions:

组别:

对照组

样本量:

20

Group:

Control group

Sample size:

干预措施:

对症处理

干预措施代码:

Intervention:

Symptomatic treatment

Intervention code:

组别:

观察组

样本量:

20

Group:

Observation group

Sample size:

干预措施:

对症处理基础上,中药滋阴清热通窍方预防性应用鼻冲洗(80ml)联合雾化吸入(10ml,20min)共14天

干预措施代码:

Intervention:

Based on symptomatic treatment, Herbal prescription for nasal irrigation(80ml) and inhalation(10ml in 20min)for 14 days

Intervention code:

样本总量 Total sample size : 40

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

朝阳

Country:

China

Province:

Beijing

City:

Chaoyang District

单位(医院):

中日友好医院

单位级别:

三级甲等

Institution/hospital:

China-Japan Friendship Hospital

Level of the institution:

Class A Level 3

测量指标:

Outcomes:

指标中文名:

嗅觉及味觉功能

指标类型:

主要指标

Outcome:

Olfactory and taste function

Type:

Primary indicator

测量时间点:

0、14±5、28±5、60±7天

测量方法:

Sniffin'sticks 嗅觉测试及三滴法味觉测试,患者自评VAS

Measure time point of outcome:

0/14±5/28±5/60±7days

Measure method:

Sniffin'sticks olfactory test and three-drop taste test, VAS score

指标中文名:

糖精试验

指标类型:

主要指标

Outcome:

Saccharin test

Type:

Primary indicator

测量时间点:

0、14±5、28±5、60±7天

测量方法:

放置糖精至下鼻甲内测,直至患者感受到甜味计算时间

Measure time point of outcome:

0/14±5/28±5/60±7days

Measure method:

Saccharin was placed into the inferior turbinate and measured until the patient felt the sweetness.

指标中文名:

鼻窦CT Lund-Mackay评分

指标类型:

次要指标

Outcome:

Lund-Mackay score of nasal CT

Type:

Secondary indicator

测量时间点:

0、60±7天

测量方法:

对双侧上颌窦、前组筛窦、后组筛窦、蝶窦、额窦和窦口鼻道复合体进行评分

Measure time point of outcome:

0/60±7days

Measure method:

Score the bilateral maxillary sinus ethmoid sinus in anterior group ethmoid sinus in posterior group sphenoid sinus frontal sinus and sinusostoma complex

指标中文名:

鼻内镜Lund-Kennedy评分

指标类型:

次要指标

Outcome:

Lund-Kennedy score of nasal endoscopy

Type:

Secondary indicator

测量时间点:

0、14±5、28±5、60±7天

测量方法:

对双侧息肉、水肿、鼻漏进行评分

Measure time point of outcome:

0/14±5/28±5/60±7days

Measure method:

score bilateral polyps water and rhinorrhea

指标中文名:

鼻-鼻窦炎视觉模拟量表

指标类型:

次要指标

Outcome:

Visual analogue scale of rhinosinusitis

Type:

Secondary indicator

测量时间点:

0、14±5、28±5、60±7天

测量方法:

患者自评

Measure time point of outcome:

0/14±5/28±5/60±7days

Measure method:

Patient self-assessment

指标中文名:

QOD-NS嗅觉相关问卷

指标类型:

次要指标

Outcome:

QOD-NS Olfactory related questionnaire

Type:

Secondary indicator

测量时间点:

0、28±5、60±7天

测量方法:

患者填写

Measure time point of outcome:

0/28±5/60±7days

Measure method:

Fill the questionnaire by patients.

指标中文名:

临床症状积分

指标类型:

主要指标

Outcome:

Clinical symptom score

Type:

Primary indicator

测量时间点:

0、14±5、28±5、60±7天

测量方法:

评估鼻塞、鼻腔分泌物、嗅觉减退、头痛4项进行评分

Measure time point of outcome:

0/14±5/28±5/60±7days

Measure method:

Evaluate nasal congestion nasal discharge anosmia and headache

指标中文名:

不良事件

指标类型:

副作用指标

Outcome:

Adverse event

Type:

Adverse events

测量时间点:

试验全程

测量方法:

患者报告

Measure time point of outcome:

Along the research

Measure method:

Reported by patients.

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

-

Randomization Procedure (please state who generates the random number sequence and by what method):

-

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

表格

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Excel

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF表收集;Excel表格管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF; Excel

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统